Assessment Status | Rapid Review Complete |
HTA ID | - |
Drug | Secukinumab |
Brand | Cosentyx® |
Indication | For the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy |
Assessment Process | |
Rapid review commissioned | 02/12/2015 |
Rapid review completed | 14/12/2015 |
Rapid review outcome | Full Pharmacoeconomic Evaluation not Recommended |
The HSE has approved reimbursement following confidential price negotiations.